Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC).
Richard Gagnon(BC Cancer Agency), Steven Yip(University of Calgary), Tarek A. Bismar(University of Calgary), Rehan M. Faridi(University of Calgary), Richard M. Lee‐Ying(Alberta Health Services), Daniel Khalaf(BC Cancer Agency), Adrian Fairey(University of Alberta), Soufiane El Hallani(Inserm), Michael Kolinsky(University of Alberta), Geoffrey Gotto(University of Calgary), John D. Lewis(University of Victoria), Divya Samuel(University of Calgary), Sarah Cook(University of Calgary), Joseph D. Ruether, Catalina Vásquez, Nimira Alimohamed(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Minal Borkar(University of Calgary)
Cited by 0
Related Papers
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
|Cancer Discovery|2018|520
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
|European Urology|2014|297
A non-randomized comparison of mindfulness-based stress reduction and healing arts programs for facilitating post-traumatic growth and spirituality in cancer outpatients
|Supportive Care in Cancer|2007|269
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233